Reports

Sale

Active Pharmaceutical Ingredients (API) Market

Global Active Pharmaceutical Ingredients (API) Market Size, Forecast: By Molecule: Small Molecule, Large Molecule; By Drug Type: Branded or Innovative Active Pharmaceutical Ingredients, Others; By Type of Manufacturer; By Potency; By API Type; By Therapeutic Application; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Global Active Pharmaceutical Ingredients (API) Market Outlook

The global active pharmaceutical ingredient market size was valued at USD 217.22 billion in 2023, driven by the increasing prevalence of diseases across the globe. The market size is anticipated to grow at a CAGR of 5.5% during the forecast period of 2024-2032 to achieve a value of USD 351.71 billion by 2032.

 

Active Pharmaceutical Ingredients (API) Market: Introduction and Overview

Active pharmaceutical ingredients (API) refers to the biologically active ingredient of a medicine. Generally, a medicine consists of several components, where the primary component is the API. Other additives are typically known as excipients. Often a drug may include many APIs, and its effect on a patient is dependent on the prescription dosage and may differ from person to person. In combination therapy, two or more active drugs are used to treat various symptoms in multiple ways.

 

Active Pharmaceutical Ingredients Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

For a range of large and small suppliers, the global active pharmaceutical ingredients (API) market is highly competitive. Companies involved in its production typically specialise in their manufacturing processes and plan their production on the basis of a combination of internal competencies and business possibilities.

 

Active Pharmaceutical Ingredients Market by Drug Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Active Pharmaceutical Ingredients (API) Market Segmentation

Market Breakup by Molecule

  • Small Molecule
  • Large Molecule

 

Market Breakup by Drug Type

  • Branded or Innovative Active Pharmaceutical Ingredients
  • Generic Active Pharmaceutical Ingredients
  • Over The Counter (OTC) Drugs

 

Market Breakup by Type of Manufacturer

  • Captive API Manufacturer 
  • Merchant API Manufacturer

 

Market Breakup by Potency

  • Low to Moderate 
  • Potent to Highly Potent

 

Market Breakup by API Type

  • Synthetic
  • Biological
  • Plant Extracts

 

Market Breakup by Therapeutic Application

  • Cardiology 
  • CNS & neurology 
  • Oncology 
  • Orthopedic 
  • Endocrinology 
  • Pulmonology 
  • Gastroenterology 
  • Nephrology 
  • Ophthalmology 
  • Other

 

Market Breakup by End User

  • Pharmaceutical and Biotechnology Industry
  • CROs
  • CMOs
  • Others

 

Market Breakup by Region

  • North America 
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Active Pharmaceutical Ingredients (API) Market Analysis

The rising proliferation of chronic conditions has led to a rise in drug demand and, thus, to an increase in the global active pharmaceutical ingredients (API) market growth. In addition, some manufacturers are investing in R&D activities in order to offer higher quality, low-cost APIs, which can help cure illnesses outside the reach of small molecular medicinal products. Therefore, pharmaceutical firms move their manufacturing facilities to developing economies and outsource their operations to maximize production and increase input costs. In addition, there is likely to be a substantial increase in the market for generic APIs as a result of a loss of patent rights for blockbuster drugs worth several billion dollars over the next few years.

 

Active Pharmaceutical Ingredients Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The growing number of blockbusters patent expiries is among the key drivers of this industry and provides a substantial chance to generic active pharmaceutical ingredients. In addition, the demand for active pharmaceutical ingredients for bio-based substances has been rising. The global biologics market is currently showing a strong growth, which is catalysed by its high power and ability to treat diseases other than small molecule medicines. This has led to a high demand for APIs and their biosimilar versions of marketed biological drugs. The ageing population, higher expenditure on healthcare, and increased prevalence of lifestyle diseases are the other factors that are catalysing the market development.

 

Active Pharmaceutical Ingredients (API) Market: Competitive Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Novartis AG
  • Sanofi 
  • Pfizer Inc. 
  • Johnson & Johnson Private Limited 
  • Abbott 
  • Teva Pharmaceutical Industries Ltd. 
  • Bausch Health Companies Inc. 
  • UCB S.A. 
  • Sunovion Pharmaceuticals Inc. 
  • Jazz Pharmaceuticals, Inc.
  • AstraZeneca
  • GSK plc
  • Takeda Pharmaceutical Company Limited 
  • Sumitomo Dainippon Pharma Co., Ltd. 
  • Cadila Pharmaceuticals

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Molecule
  • Drug Type
  • Type of Manufacturer
  • Potency
  • API Type
  • Therapeutic Application
  • End User
  • Region
Breakup by Molecule
  • Small Molecule
  • Large Molecule
Breakup by Drug Type
  • Branded or Innovative Active Pharmaceutical Ingredients
  • Generic Active Pharmaceutical Ingredients
  • Over The Counter (OTC) Drugs
Breakup by Type of Manufacturer
  • Captive API Manufacturer 
  • Merchant API Manufacturer
Breakup by Potency
  • Low to Moderate 
  • Potent to Highly Potent
Breakup by API Type
  • Synthetic
  • Biological
  • Plant Extracts
Breakup by Therapeutic Application
  • Cardiology 
  • CNS & neurology 
  • Oncology 
  • Orthopedic 
  • Endocrinology 
  • Pulmonology 
  • Gastroenterology 
  • Nephrology 
  • Ophthalmology 
  • Other
Breakup by End User
  • Pharmaceutical and Biotechnology Industry
  • CROs
  • CMOs
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Novartis AG
  • Sanofi 
  • Pfizer Inc. 
  • Johnson & Johnson Private Limited 
  • Abbott 
  • Teva Pharmaceutical Industries Ltd. 
  • Bausch Health Companies Inc. 
  • UCB S.A. 
  • Sunovion Pharmaceuticals Inc. 
  • Jazz Pharmaceuticals, Inc. 
  • AstraZeneca 
  • GSK plc 
  • Takeda Pharmaceutical Company Limited 
  • Sumitomo Dainippon Pharma Co., Ltd. 
  • Cadila Pharmaceuticals

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Active Pharmaceutical Ingredients (API) Market Overview
 
    3.1    Global Active Pharmaceutical Ingredients (API) Market Historical Value (2017-2023) 
    3.2    Global Active Pharmaceutical Ingredients (API) Market Forecast Value (2024-2032)
4    Global Active Pharmaceutical Ingredients (API) Market Landscape
    4.1    Global Active Pharmaceutical Ingredients (API) Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Active Pharmaceutical Ingredients (API) Product Landscape
        4.2.1    Analysis by Molecule
        4.2.2    Analysis by Drug Type
        4.2.3    Analysis by Type of Manufacturer
        4.2.4    Analysis by Potency
        4.2.5    Analysis by API Type
        4.2.6    Analysis by Therapeutic Application
5    Global Active Pharmaceutical Ingredients (API) Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Active Pharmaceutical Ingredients (API) Market Segmentation 
    6.1    Global Active Pharmaceutical Ingredients (API) Market by Molecule
        6.1.1    Market Overview 
        6.1.2    Small Molecule
        6.1.3    Large Molecule
    6.2    Global Active Pharmaceutical Ingredients (API) Market by Drug Type
        6.2.1    Market Overview
        6.2.2    Branded or Innovative Active Pharmaceutical Ingredients 
        6.2.3    Generic Active Pharmaceutical Ingredients
        6.2.4    Over The Counter (OTC) Drugs
    6.3    Global Active Pharmaceutical Ingredients (API) Market by Type of Manufacturer
        6.3.1    Market Overview 
        6.3.2    Captive API Manufacturer 
        6.3.3    Merchant API Manufacturer
    6.4    Global Active Pharmaceutical Ingredients (API) Market by Potency
        6.4.1    Market Overview
        6.4.2    Low to Moderate 
        6.4.3    Potent to Highly Potent
    6.5    Global Active Pharmaceutical Ingredients (API) Market by API Type
        6.5.1    Market Overview
        6.5.2    Synthetic
        6.5.3    Biological
        6.5.4    Plant Extracts
    6.6    Global Active Pharmaceutical Ingredients (API) Market by Therapeutic Application
        6.6.1    Market Overview
        6.6.2    Cardiology 
        6.6.3    CNS & neurology 
        6.6.4    Oncology 
        6.6.5    Orthopedic 
        6.6.6    Endocrinology 
        6.6.7    Pulmonology 
        6.6.8    Gastroenterology 
        6.6.9    Nephrology 
        6.6.10    Ophthalmology 
        6.6.11    Other  
    6.7    Global Active Pharmaceutical Ingredients (API) Market by End User
        6.7.1    Pharmaceutical and Biotechnology Industry
        6.7.2    CROs
        6.7.3    CMOs
        6.7.4    Others
    6.8    Global Active Pharmaceutical Ingredients (API) Market by Region
        6.8.1    Market Overview
        6.8.2    North America 
        6.8.3    Europe
        6.8.4    Asia Pacific
        6.8.5    Latin America
        6.8.6    Middle East and Africa
7    North America Active Pharmaceutical Ingredients (API) Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Active Pharmaceutical Ingredients (API) Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Active Pharmaceutical Ingredients (API) Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Active Pharmaceutical Ingredients (API) Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Active Pharmaceutical Ingredients (API) Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    Novartis AG
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    Sanofi 
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Pfizer Inc. 
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Johnson & Johnson Private Limited 
        17.4.1    Financial Analysis
        17.4.2    Financial Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Abbott 
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Teva Pharmaceutical Industries Ltd. 
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Bausch Health Companies Inc. 
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    UCB S.A. 
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Sunovion Pharmaceuticals Inc. 
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Jazz Pharmaceuticals, Inc. 
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    AstraZeneca 
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    GSK plc 
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
    17.13    Takeda Pharmaceutical Company Limited 
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications
    17.14    Sumitomo Dainippon Pharma Co., Ltd. 
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications
    17.15    Cadila Pharmaceuticals 
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications
18    Global Active Pharmaceutical Ingredients (API) Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of USD 217.22 billion in 2023, driven by the rising healthcare sector.

The market is expected to grow at a CAGR of about 5.5% during the forecast period of 2024-2032 to reach USD 351.71 billion by 2032.

The growth of the market is driven by factors like rising demand from the emerging nations, growing biologics market, increasing healthcare expenditure, and the rising R&D investments.

The key trend guiding the growth of the market includes the upcoming expiry of blockbuster drugs patents, which provides a significant growth potential for generic active pharmaceutical ingredients.

The major regional markets for the product include North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

The major molecules can be categorised into small and large molecule.

The types of the product can be categorised into branded or innovative active pharmaceutical ingredients, generic active pharmaceutical ingredients, and over the counter (OTC) drugs.

The key manufacturers in the market can be divided into captive and merchant API manufacturer.

The potency of the product can be categorised into low to moderate and potent to highly potent.

The product finds wide applications in cardiology, CNS and neurology, oncology, orthopaedic, endocrinology, pulmonology, gastroenterology, nephrology, and ophthalmology, among others.

The end-users of the product include pharmaceutical and biotechnology industry, CROs, and CMOs, among others.

The key players can be categorised into Novartis AG, Sanofi, Pfizer Inc., Johnson & Johnson Private Limited, Abbott, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB S.A., Sunovion Pharmaceuticals Inc., Jazz Pharmaceuticals, Inc., AstraZeneca, GSK plc, Takeda Pharmaceutical Company Limited, Sumitomo Dainippon Pharma Co., Ltd., and Cadila Pharmaceuticals.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER